Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Share:
Related MDCO
Earnings Scheduled For February 17, 2016
The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors
Related BMY
Bristol-Myers Squibb Target, Estimates Under Review At Goldman Sachs
Earnings Scheduled For April 28, 2016
What Exelixis' Approval In Kidney Cancer Means For Patients (Seeking Alpha)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News

 

Related Articles (MDCO + BMY)

View Comments and Join the Discussion!